Literature DB >> 19305783

How good is good enough? Standards in policy decisions to cover new health technologies.

Mita Giacomini1.   

Abstract

Health technology coverage decisions require reasonable criteria, for example, the requirement that a technology be effective, efficient, legitimate in purpose, acceptable in its effects, safe and so on. The leap from such criteria to decisions requires not only evidence, but also standards. Decision-makers must specify their values, which apply in general, regarding what is "good enough" before they can judge any technology in particular. This paper will do the following: (1) describe the key analytic tasks involved in defining coverage criteria and their standards, (2) identify some of the policy applications of explicit standards to coverage decisions and (3) review the policy uses of such standards, including some challenges they pose. The problem of identifying cost-effectiveness standards will be used to illustrate key issues. It is argued that a precedent-based understanding of standards is relevant in the Canadian policy context, where fairness is crucial. Studies of actual decision-making that seek standards inductively have been misguided in their focus on central tendencies to the neglect of outliers (precedents), while deductive analyses and rules of thumb have been ungrounded in prevailing values.

Year:  2007        PMID: 19305783      PMCID: PMC2645181     

Source DB:  PubMed          Journal:  Healthc Policy        ISSN: 1715-6572


  15 in total

Review 1.  The which-hunt: assembling health technologies for assessment and rationing.

Authors:  M K Giacomini
Journal:  J Health Polit Policy Law       Date:  1999-08       Impact factor: 2.265

2.  Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996).

Authors:  B George; A Harris; A Mitchell
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Grading quality of evidence and strength of recommendations.

Authors:  David Atkins; Dana Best; Peter A Briss; Martin Eccles; Yngve Falck-Ytter; Signe Flottorp; Gordon H Guyatt; Robin T Harbour; Margaret C Haugh; David Henry; Suzanne Hill; Roman Jaeschke; Gillian Leng; Alessandro Liberati; Nicola Magrini; James Mason; Philippa Middleton; Jacek Mrukowicz; Dianne O'Connell; Andrew D Oxman; Bob Phillips; Holger J Schünemann; Tessa Tan-Torres Edejer; Helena Varonen; Gunn E Vist; John W Williams; Stephanie Zaza
Journal:  BMJ       Date:  2004-06-19

4.  National Institute for Clinical Excellence and its value judgments.

Authors:  Michael D Rawlins; Anthony J Culyer
Journal:  BMJ       Date:  2004-07-24

5.  Quality, innovation, and value for money: NICE and the British National Health Service.

Authors:  Steven D Pearson; Michael D Rawlins
Journal:  JAMA       Date:  2005-11-23       Impact factor: 56.272

6.  Medicare and cost-effectiveness analysis.

Authors:  Peter J Neumann; Allison B Rosen; Milton C Weinstein
Journal:  N Engl J Med       Date:  2005-10-06       Impact factor: 91.245

Review 7.  One of these things is not like the others: the idea of precedence in health technology assessment and coverage decisions.

Authors:  Mita Giacomini
Journal:  Milbank Q       Date:  2005       Impact factor: 4.911

8.  Bringing 'the public' into health technology assessment and coverage policy decisions: from principles to practice.

Authors:  Julia Abelson; Mita Giacomini; Pascale Lehoux; Francois-Pierre Gauvin
Journal:  Health Policy       Date:  2006-09-22       Impact factor: 2.980

9.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.

Authors:  A Laupacis; D Feeny; A S Detsky; P X Tugwell
Journal:  CMAJ       Date:  1992-02-15       Impact factor: 8.262

10.  How stable are people's preferences for giving priority to severely ill patients?

Authors:  P A Ubel
Journal:  Soc Sci Med       Date:  1999-10       Impact factor: 4.634

View more
  9 in total

1.  Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk.

Authors:  Dominic Mitchell; Jason R Guertin; Jacques LeLorier
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

Review 2.  Societal values in the allocation of healthcare resources: is it all about the health gain?

Authors:  Tania Stafinski; Devidas Menon; Deborah Marshall; Timothy Caulfield
Journal:  Patient       Date:  2011       Impact factor: 3.883

3.  A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention.

Authors:  Dominic Mitchell; Jason R Guertin; Anick Dubois; Marie-Pierre Dubé; Jean-Claude Tardif; Ange Christelle Iliza; Fiorella Fanton-Aita; Alexis Matteau; Jacques LeLorier
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

4.  Economic evaluation and cost-effectiveness thresholds: signals to firms and implications for R & D investment and innovation.

Authors:  John A Vernon; Robert Goldberg; Joseph Golec
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 5.  Health technology funding decision-making processes around the world: the same, yet different.

Authors:  Tania Stafinski; Devidas Menon; Donald J Philippon; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2011-06       Impact factor: 4.981

6.  A Cost-Utility Analysis of the Syncope: Pacing or Recording in The Later Years (SPRITELY) Trial.

Authors:  Mark Hofmeister; Robert S Sheldon; Eldon Spackman; Satish R Raj; Mario Talajic; Giuliano Becker; Vidal Essebag; Deborah Ritchie; Carlos A Morillo; Andrew Krahn; Shahana Safdar; Connor Maxey; Fiona Clement
Journal:  CJC Open       Date:  2022-03-29

7.  From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmaking.

Authors:  Lalla Aïda Guindo; Monika Wagner; Rob Baltussen; Donna Rindress; Janine van Til; Paul Kind; Mireille M Goetghebeur
Journal:  Cost Eff Resour Alloc       Date:  2012-07-18

8.  The impact of preoperative patient characteristics on the cost-effectiveness of total hip replacement: a cohort study.

Authors:  Matthias Vogl; Rainer Wilkesmann; Christian Lausmann; Werner Plötz
Journal:  BMC Health Serv Res       Date:  2014-08-15       Impact factor: 2.655

9.  Administrative Process and Criteria Ranking for Drug Entering Health Insurance List in Iran-TOPSIS-Based Consensus Model.

Authors:  Amir Viyanchi; Ali Rajabzadeh Ghatari; Hamid Reza Rasekh; HamidReza SafiKhani
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.